Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Probenecid-clofibrate interaction

J R Veenendaal, P M Brooks, P J Meffin

    Clinical Pharmacology and Therapeutics
    |March 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Probenecid significantly increased free clofibric acid plasma levels in healthy men by reducing its renal and metabolic clearance. This suggests probenecid inhibits clofibric acid conjugation with glucuronide.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Australia needs an Ombudsman or Office for Research Integrity.

    Internal medicine journal·2016
    Same author

    The management of rheumatoid arthritis.

    The Australian journal of physiotherapy·2014
    Same author

    The patient is the teacher: ambulatory patient-centred student-based interprofessional education where the patient is the teacher who improves patient care outcomes.

    Internal medicine journal·2013
    Same author

    The clinical significance of indomethacin-probenecid interaction.

    British journal of clinical pharmacology·2012
    Same author

    The effect of frusemide on indomethacin plasma levels.

    British journal of clinical pharmacology·2012
    Same author

    Over the counter (OTC) oral remedies for arthritis and rheumatism: how effective are they?

    Inflammopharmacology·2008
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Area of Science:

    • Pharmacokinetics
    • Drug Metabolism
    • Renal Physiology

    Background:

    • Clofibric acid is a lipid-lowering agent.
    • Understanding drug interactions is crucial for patient safety.

    Purpose of the Study:

    • To investigate the effect of probenecid on clofibric acid disposition.
    • To determine if probenecid alters the renal and metabolic clearance of clofibric acid.

    Main Methods:

    • Four healthy men received clofibrate for one week.
    • Probenecid was administered concurrently with clofibrate in a separate phase.
    • Plasma concentrations of free clofibric acid and its glucuronide were measured.

    Main Results:

    • Free clofibric acid plasma concentrations increased significantly with probenecid co-administration.

    Related Experiment Videos

  • No clofibric acid glucuronide was detected in plasma during either treatment.
  • Urinary excretion fractions of clofibric acid and its metabolites remained unchanged.

    • Conclusions:

    • Probenecid reduces both renal and metabolic clearance of clofibric acid.
    • This reduction is likely due to probenecid inhibiting clofibric acid glucuronidation.
    • The findings highlight a significant drug interaction impacting clofibric acid pharmacokinetics.